Cargando…
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
BACKGROUND: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of administration in a dose-dense regimen have not been defined yet. METHODS: From...
Autores principales: | Fountzilas, George, Dafni, Urania, Papadimitriou, Christos, Timotheadou, Eleni, Gogas, Helen, Eleftheraki, Anastasia G, Xanthakis, Ioannis, Christodoulou, Christos, Koutras, Angelos, Papandreou, Christos N, Papakostas, Pavlos, Miliaras, Spyros, Markopoulos, Christos, Dimitrakakis, Constantine, Korantzopoulos, Panagiotis, Karanikiotis, Charisios, Bafaloukos, Dimitrios, Kosmidis, Paris, Samantas, Epaminontas, Varthalitis, Ioannis, Pavlidis, Nicholas, Pectasides, Dimitrios, Dimopoulos, Meletios-Athanassios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223601/ https://www.ncbi.nlm.nih.gov/pubmed/25026897 http://dx.doi.org/10.1186/1471-2407-14-515 |
Ejemplares similares
-
XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
por: Pectasides, Dimitrios, et al.
Publicado: (2012) -
Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
por: Fountzilas, George, et al.
Publicado: (2013) -
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
por: Fountzilas, George, et al.
Publicado: (2016) -
A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)
por: Pentheroudakis, George, et al.
Publicado: (2014) -
Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative
por: Fountzilas, Elena, et al.
Publicado: (2020)